Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Processa Pharmaceuticals, Inc. stock logo
PCSA
Processa Pharmaceuticals
$0.27
+11.3%
$0.27
$0.15
$3.10
$3.17M1.361.10 million shs3.93 million shs
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
$3.94
-17.2%
$3.88
$2.35
$23.52
$2.32M0.28544,976 shs567,383 shs
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
$0.00
$0.00
$0.02
$717K1.1384,009 shs27,368 shs
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
$0.80
+2.6%
$1.13
$0.73
$737.44
$2.93M0.82749,471 shs87,684 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Processa Pharmaceuticals, Inc. stock logo
PCSA
Processa Pharmaceuticals
+11.35%+5.16%+12.52%-51.21%-85.17%
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
-17.23%-42.73%+29.10%+9.68%-81.96%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00%+18.18%+30.00%+160.00%-87.62%
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
+2.57%-2.56%-33.97%-76.97%-99.59%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Processa Pharmaceuticals, Inc. stock logo
PCSA
Processa Pharmaceuticals
2.7062 of 5 stars
3.55.00.00.00.01.71.3
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
1.1279 of 5 stars
0.05.00.00.02.91.70.0
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
1.8743 of 5 stars
3.04.00.00.01.30.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Processa Pharmaceuticals, Inc. stock logo
PCSA
Processa Pharmaceuticals
3.00
Buy$6.002,148.03% Upside
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
0.00
N/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00
N/AN/AN/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
2.00
Hold$350.0043,704.76% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Processa Pharmaceuticals, Inc. stock logo
PCSA
Processa Pharmaceuticals
N/AN/AN/AN/A$4.05 per shareN/A
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
N/AN/AN/AN/A$0.83 per shareN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$60.32M0.01N/AN/AN/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/AN/AN/AN/A$10.17 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Processa Pharmaceuticals, Inc. stock logo
PCSA
Processa Pharmaceuticals
-$11.12M-$3.08N/AN/AN/AN/A-195.21%-163.06%8/12/2025 (Estimated)
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
-$5M-$13.11N/AN/AN/A-308.97%-228.73%8/12/2025 (Estimated)
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
-$572.84MN/A0.00N/AN/AN/AN/AN/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
-$20.29M-$823.47N/AN/AN/AN/A-362.76%-79.65%N/A

Latest SRNE, WINT, PCSA, and PTIX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
-$39.00-$4.63+$34.37-$4.63$2.20 millionN/A
5/13/2025Q1 2025
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
N/A-$2.75N/A-$2.75N/AN/A
5/8/2025Q1 2025
Processa Pharmaceuticals, Inc. stock logo
PCSA
Processa Pharmaceuticals
-$0.77-$0.30+$0.47-$0.30N/AN/A
3/31/2025Q4 2024
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
N/A-$3.36N/A-$0.24N/AN/A
3/20/2025Q4 2024
Processa Pharmaceuticals, Inc. stock logo
PCSA
Processa Pharmaceuticals
-$0.92-$0.74+$0.18-$0.74N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Processa Pharmaceuticals, Inc. stock logo
PCSA
Processa Pharmaceuticals
N/AN/AN/AN/AN/A
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
N/AN/AN/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/AN/AN/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Processa Pharmaceuticals, Inc. stock logo
PCSA
Processa Pharmaceuticals
N/A
3.97
3.97
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
N/A
1.80
1.80
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/A
0.27
0.27
CompanyEmployeesShares OutstandingFree FloatOptionable
Processa Pharmaceuticals, Inc. stock logo
PCSA
Processa Pharmaceuticals
2011.88 million2.84 millionNot Optionable
Protagenic Therapeutics, Inc. stock logo
PTIX
Protagenic Therapeutics
2589,0004.71 millionNot Optionable
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
800551.28 million536.95 millionNo Data
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
303.66 million11.01 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Processa Pharmaceuticals stock logo

Processa Pharmaceuticals NASDAQ:PCSA

$0.27 +0.03 (+11.35%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$0.28 +0.01 (+3.78%)
As of 08:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

Protagenic Therapeutics stock logo

Protagenic Therapeutics NASDAQ:PTIX

$3.94 -0.82 (-17.23%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$4.14 +0.21 (+5.20%)
As of 08:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

Sorrento Therapeutics stock logo

Sorrento Therapeutics NASDAQ:SRNE

$0.0013 0.00 (0.00%)
As of 05/27/2025 03:53 PM Eastern

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

Windtree Therapeutics stock logo

Windtree Therapeutics NASDAQ:WINT

$0.80 +0.02 (+2.57%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$0.82 +0.02 (+3.13%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.